• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by aTyr Pharma Inc.

    3/26/26 4:09:23 PM ET
    $ATYR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ATYR alert in real time by email
    DEFA14A 1 defa14a_2026_naa_proxy_c.htm DEFA14A DEFA14A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A INFORMATION

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No. )

     

    Filed by the Registrant 

    Filed by a party other than the Registrant 

     

    Check the appropriate box:

     Preliminary Proxy Statement

     Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     Definitive Proxy Statement

     Definitive Additional Materials

     Soliciting Material under § 240.14a-12

    ATYR PHARMA, INC.

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     No fee required

     Fee paid previously with preliminary materials

     Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     


     

     

    img234901345_0.jpg

    NAME & ADDRESS HERE You must use the 11-digit Control Number located in the box to vote via Internet, or to request proxy materials. Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting of Stockholders To Be Held on May 11, 2026 at 9:00a.m. Pacific Time. This communication is not a form of voting and presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. The Notice, Proxy Statement, Annual Report, and directions to attend the meeting are available at https://web.viewproxy.com/atyr/2026 If you want to receive a paper or email copy of these documents, you must request one by following the instructions on the reverse side of this Notice on or before April 28, 2026 to facilitate timely delivery. There is no charge to you for requesting a copy. Important information regarding the availability of the Company’s proxy materials, instructions for accessing your proxy materials and voting online, and instructions for requesting paper or e-mail copies of your proxy materials are outlined in this Notice. CONTROL NUMBER STOCKHOLDERS ARE CORDIALLY INVITED TO ATTEND THE ANNUAL MEETING. To the Stockholders of ATYR PHARMA, INC.: The 2026 Annual Meeting of Stockholders of ATYR PHARMA, INC. will be held on May 11, 2026 at 9:00 a.m. Pacific Time. Notice is hereby given that the Annual Meeting of Stockholders of ATYR PHARMA, INC. will be held on May 11, 2026 at 9:00 a.m. Pacific Time at the offices of aTyr Pharma, Inc., 10240 Sorrento Valley Road, San Diego, CA 92121 for the following purposes: The Board recommends a vote “FOR” each of the Board of Directors’ nominees listed in Proposal 1 and “FOR” Proposals 2, 3, 4, and 5. 1. To elect three Class II directors, as nominated by the Company’s Board of Directors (the “Board of Directors”), to hold office until the 2029 annual meeting of stockholders or until their successors are duly elected and qualified; 01. Eric Benevich 02. Timothy P. Coughlin 03. Jane A. Gross, Ph.D. 2. To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026; 3. To approve, on an advisory basis, the compensation of the Company’s named executive officers; 4. To approve an amendment to the aTyr Pharma, Inc. 2015 Stock Option and Incentive Plan, as amended; 5. To approve an amendment to the Company’s Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 170,000,000 to 340,000,000 shares; and 6. To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.

     

     

     

     

     

     


     

     

     

     

    img234901345_1.jpg

     

    The Securities and Exchange Commission rules permit us to make our proxy materials available to our stockholders via the Internet. Materials for this Annual Meeting and future meetings may be requested by one of the following methods: CONTROL NUMBER Internet Go to https://web.viewproxy.com/atyr/2026. Have the 11-digit Control Number available when you access the website and follow the instructions. Telephone Call 1-877-777-2857 Toll Free E-Mail By e-mail at: [email protected] * If requesting material by e-mail, please send a blank e-mail with the company name and your 11-digit Control Number in the subject line. No other requests, instructions, or other inquiries should be included within this email request. VOTING METHODS Via Internet prior to the Annual Meeting: Go to https://web.viewproxy.com/atyr/2026. Have your 11-digit Control Number available and follow the prompts. • Your electronic vote prior to the Annual Meeting authorizes the named proxies to vote your shares in the same manner as if you marked, signed, dated, and returned a proxy card. Via Mail: Request a paper copy of the materials which includes Follow the instructions on the proxy a proxy card. card for voting by mail. Via Telephone: Call 1-866-402-3905 Use any touch-tone telephone to vote your proxy. Have your proxy card available when you call. Follow the voting instructions to vote your shares.


    Get the next $ATYR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATYR

    DatePrice TargetRatingAnalyst
    9/16/2025$1.50Outperform → Sector Perform
    RBC Capital Mkts
    9/15/2025$1.00Overweight → Equal Weight
    Wells Fargo
    9/15/2025Buy → Neutral
    H.C. Wainwright
    9/15/2025$1.00Outperform → Market Perform
    Leerink Partners
    9/15/2025Overweight → Neutral
    Cantor Fitzgerald
    2/18/2025$16.00Outperform
    Leerink Partners
    1/6/2025Overweight
    Cantor Fitzgerald
    10/4/2024$17.00Overweight
    Wells Fargo
    More analyst ratings

    $ATYR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update

    Company scheduled to meet with the FDA in mid-April 2026 to review the results of the Phase 3 EFZO-FIT™ study and determine the path forward for efzofitimod in pulmonary sarcoidosis.  Phase 2 EFZO-CONNECT™ study of efzofitimod in systemic sclerosis-related interstitial lung disease (SSc-ILD) on track to complete enrollment in the first half of 2026. Ended 2025 with $80.9 million in cash, cash equivalents, restricted cash and investments. SAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase pla

    3/5/26 4:01:00 PM ET
    $ATYR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SAN DIEGO, Feb. 20, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or "the Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Compensation Committee of aTyr's Board of Directors has granted two employees nonstatutory stock options to purchase an aggregate of 12,200 shares of aTyr's common stock, each with an exercise price of $0.98 per share, which is equal to the closing price of aTyr's common stock on the Nasdaq Capital Market on February 17, 2026, the effective date of the grants. These stock awards were granted as an inducement ma

    2/20/26 4:01:00 PM ET
    $ATYR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference

    SAN DIEGO, Feb. 18, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at the Leerink Partners Global Healthcare Conference, which is scheduled to take place March 8 – 11, 2026, in Miami, FL. Details of the presentation appear below: Conference: Leerink Partners Global Healthcare ConferenceDate: Wednesday, March 11, 2026Time: 8:00am EDTLocation: Miami, FLFormat: Corporate Presentation In addition to the presentation, company m

    2/18/26 8:00:00 AM ET
    $ATYR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATYR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Shukla Sanjay converted options into 10,375 shares and sold $3,655 worth of shares (3,745 units at $0.98), increasing direct ownership by 5% to 153,553 units (SEC Form 4)

    4 - aTYR PHARMA INC (0001339970) (Issuer)

    2/4/26 7:17:28 PM ET
    $ATYR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Financial Officer Broadfoot Jill Marie converted options into 3,750 shares and sold $1,521 worth of shares (1,558 units at $0.98), increasing direct ownership by 6% to 37,296 units (SEC Form 4)

    4 - aTYR PHARMA INC (0001339970) (Issuer)

    2/4/26 7:15:03 PM ET
    $ATYR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    General Counsel Denyes Nancy converted options into 2,687 shares and sold $1,091 worth of shares (1,118 units at $0.98), increasing direct ownership by 5% to 33,124 units (SEC Form 4)

    4 - aTYR PHARMA INC (0001339970) (Issuer)

    2/4/26 7:12:45 PM ET
    $ATYR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATYR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Schimmel Paul bought $911,801 worth of shares (1,000,000 units at $0.91) (SEC Form 4)

    4 - aTYR PHARMA INC (0001339970) (Issuer)

    10/9/25 6:30:21 PM ET
    $ATYR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Gross Jane A bought $15,000 worth of shares (3,750 units at $4.00), increasing direct ownership by 62% to 9,750 units (SEC Form 4)

    4 - aTYR PHARMA INC (0001339970) (Issuer)

    3/17/25 7:07:42 PM ET
    $ATYR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Schimmel Paul bought $184,613 worth of shares (100,000 units at $1.85) (SEC Form 4)

    4 - aTYR PHARMA INC (0001339970) (Issuer)

    7/24/24 5:29:51 PM ET
    $ATYR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATYR
    SEC Filings

    View All

    $ATYR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    SEC Form DEFA14A filed by aTyr Pharma Inc.

    DEFA14A - aTYR PHARMA INC (0001339970) (Filer)

    3/26/26 4:09:23 PM ET
    $ATYR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by aTyr Pharma Inc.

    SCHEDULE 13G/A - aTYR PHARMA INC (0001339970) (Subject)

    3/26/26 4:08:52 PM ET
    $ATYR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form DEF 14A filed by aTyr Pharma Inc.

    DEF 14A - aTYR PHARMA INC (0001339970) (Filer)

    3/26/26 4:08:09 PM ET
    $ATYR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    aTyr Pharma downgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts downgraded aTyr Pharma from Outperform to Sector Perform and set a new price target of $1.50

    9/16/25 8:00:57 AM ET
    $ATYR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    aTyr Pharma downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded aTyr Pharma from Overweight to Equal Weight and set a new price target of $1.00

    9/15/25 1:24:32 PM ET
    $ATYR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    aTyr Pharma downgraded by H.C. Wainwright

    H.C. Wainwright downgraded aTyr Pharma from Buy to Neutral

    9/15/25 12:10:02 PM ET
    $ATYR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATYR
    Leadership Updates

    Live Leadership Updates

    View All

    aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise

    SAN DIEGO, March 26, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise. Ms. Rayes brings over 25 years of experience building and leading commercial organizations at biotechnology and pharmaceutical companies, including leading rare disease product launches. She will serve as a member of the Company's executive leadership team, overseeing global commercial strategy and operations for the efzofitimod prog

    3/26/25 8:00:00 AM ET
    $ATYR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    aTyr Pharma Announces the Appointment of Eric Benevich to its Board of Directors

    SAN DIEGO, Dec. 12, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the appointment of Eric Benevich to the Company's Board of Directors, effective as of December 10, 2024. Mr. Benevich currently serves as Chief Commercial Officer at Neurocrine Biosciences, Inc. (Neurocrine). "We are excited to welcome Eric Benevich to the Board of Directors," said Timothy P. Coughlin, Chairman of the Board of aTyr. "His extensive background bringing new products to market and the knowledge and experti

    12/12/24 4:00:00 PM ET
    $ATYR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    aTyr Pharma Announces Appointment of Jayant Aphale, PhD, as Vice President of Technical Operations

    SAN DIEGO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or "the Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the appointment of Jayant Aphale, Ph.D., as Vice President, Technical Operations. Dr. Aphale will serve as a member of the Company's executive leadership team, overseeing manufacturing activities at contract development and manufacturing organizations and implementing strategies related to the continuous improvement of commercial manufacturing, supply chain management, process development of new products and product lif

    8/6/24 8:00:00 AM ET
    $ATYR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATYR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by aTyr Pharma Inc.

    SC 13G/A - aTYR PHARMA INC (0001339970) (Subject)

    11/14/24 6:51:17 PM ET
    $ATYR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by aTyr Pharma Inc.

    SC 13G - aTYR PHARMA INC (0001339970) (Subject)

    10/15/24 5:01:55 PM ET
    $ATYR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by aTyr Pharma Inc.

    SC 13G/A - aTYR PHARMA INC (0001339970) (Subject)

    10/7/24 1:36:35 PM ET
    $ATYR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATYR
    Financials

    Live finance-specific insights

    View All

    aTyr Pharma Announces Topline Results from Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis

    Study did not meet primary endpoint in change from baseline in mean daily oral corticosteroid (OCS) dose at week 48, although clinical benefit for efzofitimod observed across multiple study parameters. 52.6% of patients treated with 5.0 mg/kg efzofitimod achieved complete steroid withdrawal at week 48 vs 40.2% on placebo (p=0.0919). Clinical improvement in King's Sarcoidosis Questionnaire (KSQ)-Lung score at week 48 observed in the 5.0 mg/kg efzofitimod treatment group vs placebo (p=0.0479). Greater proportion of patients achieved complete steroid withdrawal at week 48 with a KSQ-Lung score improvement in the 5.0 mg/kg efzofitimod treatment group (29.5%) vs placebo (14.4%) (p=0.0199

    9/15/25 7:30:00 AM ET
    $ATYR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update

    Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025. Fourth positive DSMB review for efzofitimod in Phase 3 EFZO-FIT™ study reinforces its favorable safety profile. Publication in Science Translational Medicine validates efzofitimod's mechanism of action. Company to host conference call and webcast today, March 13th at 5:00 p.m. EDT / 2:00 p.m. PDT. SAN DIEGO, March 13, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announc

    3/13/25 4:01:00 PM ET
    $ATYR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2024 Financial Results

    SAN DIEGO, March 04, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it will report fourth quarter and full year 2024 financial results and provide a corporate update after the market close on Thursday, March 13, 2025. Management will host a conference call and webcast to review the results and provide an operational update. Conference Call and Webcast Details:Date: Thursday, March 13, 2025Time: 5:00 p.m. EDT / 2:00 p.m. PDTDial-In Registration: https://register.vevent.com/register/BI00725a32705e4ee3b22d05

    3/4/25 8:00:00 AM ET
    $ATYR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care